Improvement	O
in	O
Exercise	O
Capacity	O
by	O
Exercise	O
Training	O
Associated	O
With	O
Favorable	B:C1333602
Clinical	I:C1333602
Outcomes	I:C1333602
in	O
Advanced	O
Heart	I:C0018801
Failure	I:C0018801
With	O
High	O
B	O
-	I:C0054015
Type	I:C0054015
Natriuretic	I:C0054015
Peptide	I:C0054015
Level	O
.	O

Improvement	O
in	O
Exercise	O
Capacity	O
by	O
Exercise	O
Training	O
Associated	O
With	O
Favorable	O
Clinical	I:C1333602
Outcomes	I:C1333602
in	O
Advanced	B:C0018801
Heart	I:C0018801
Failure	I:C0018801
With	O
High	O
B	O
-	I:C0054015
Type	I:C0054015
Natriuretic	I:C0054015
Peptide	I:C0054015
Level	O
.	O

Improvement	O
in	O
Exercise	O
Capacity	O
by	O
Exercise	O
Training	O
Associated	O
With	O
Favorable	O
Clinical	I:C1333602
Outcomes	I:C1333602
in	O
Advanced	O
Heart	I:C0018801
Failure	I:C0018801
With	O
High	O
B	B:C0054015
-	I:C0054015
Type	I:C0054015
Natriuretic	I:C0054015
Peptide	I:C0054015
Level	O
.	O

The	O
efficacy	O
of	O
exercise	O
training	O
(	O
ET	O
)	O
programs	O
and	O
its	O
relationship	O
with	O
long	O
-	O
term	O
clinical	O
outcomes	O
in	O
advanced	B:C0018801
heart	I:C0018801
failure	I:C0018801
(	O
heart	O
failure	I:C0018801
)	O
patients	O
with	O
high	O
levels	O
of	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
(	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
)	O
remain	O
uncertain	O
.	O

The	O
efficacy	O
of	O
exercise	O
training	O
(	O
ET	O
)	O
programs	O
and	O
its	O
relationship	O
with	O
long	O
-	O
term	O
clinical	O
outcomes	O
in	O
advanced	O
heart	I:C0018801
failure	I:C0018801
(	O
heart	B:C0018801
failure	I:C0018801
)	O
patients	O
with	O
high	O
levels	O
of	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
(	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
)	O
remain	O
uncertain	O
.	O

The	O
efficacy	O
of	O
exercise	O
training	O
(	O
ET	O
)	O
programs	O
and	O
its	O
relationship	O
with	O
long	O
-	O
term	O
clinical	O
outcomes	O
in	O
advanced	O
heart	I:C0018801
failure	I:C0018801
(	O
heart	O
failure	I:C0018801
)	O
patients	O
with	O
high	O
levels	O
of	O
B	B:C0054015
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
(	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
)	O
remain	O
uncertain	O
.	O

The	O
efficacy	O
of	O
exercise	O
training	O
(	O
ET	O
)	O
programs	O
and	O
its	O
relationship	O
with	O
long	O
-	O
term	O
clinical	O
outcomes	O
in	O
advanced	O
heart	I:C0018801
failure	I:C0018801
(	O
heart	O
failure	I:C0018801
)	O
patients	O
with	O
high	O
levels	O
of	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
(	O
B	B:C0054015
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
)	O
remain	O
uncertain	O
.	O

We	O
studied	B:C2603343
340	O
consecutive	O
heart	O
failure	I:C0018801
patients	O
with	O
ejection	O
fraction	I:C0489482
(	O
ejection	O
fraction	I:C0489482
)	O
<	O
45	O
%	O
who	O
completed	O
a	O
3	O
-	O
month	O
ET	O
program	O
.	O

We	O
studied	O
340	O
consecutive	O
heart	B:C0018801
failure	I:C0018801
patients	O
with	O
ejection	O
fraction	I:C0489482
(	O
ejection	O
fraction	I:C0489482
)	O
<	O
45	O
%	O
who	O
completed	O
a	O
3	O
-	O
month	O
ET	O
program	O
.	O

We	O
studied	O
340	O
consecutive	O
heart	O
failure	I:C0018801
patients	O
with	O
ejection	B:C0489482
fraction	I:C0489482
(	O
ejection	O
fraction	I:C0489482
)	O
<	O
45	O
%	O
who	O
completed	O
a	O
3	O
-	O
month	O
ET	O
program	O
.	O

We	O
studied	O
340	O
consecutive	O
heart	O
failure	I:C0018801
patients	O
with	O
ejection	O
fraction	I:C0489482
(	O
ejection	B:C0489482
fraction	I:C0489482
)	O
<	O
45	O
%	O
who	O
completed	O
a	O
3	O
-	O
month	O
ET	O
program	O
.	O

Patients	O
with	O
B	B:C0054015
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
≥	O
200	O
pg/	O
mL	O
(	O
High	O
-	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
,	O
n=170	O
)	O
had	O
more	O
advanced	O
heart	O
failure	I:C0018801
characteristics	O
,	O
including	O
lower	O
EF	I:C0743400
(	O
25.0	O
±8.6	O
%	O
vs.	O
28.1±8.0	O
%	O
,	O
P=0.0008	O
)	O
,	O
than	O
those	O
with	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
<	O
200	O
pg/	O
mL	O
.	O

Patients	O
with	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
≥	O
200	O
pg/	O
mL	O
(	O
High	O
-	O
B	B:C0054015
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
,	O
n=170	O
)	O
had	O
more	O
advanced	O
heart	O
failure	I:C0018801
characteristics	O
,	O
including	O
lower	O
EF	I:C0743400
(	O
25.0	O
±8.6	O
%	O
vs.	O
28.1±8.0	O
%	O
,	O
P=0.0008	O
)	O
,	O
than	O
those	O
with	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
<	O
200	O
pg/	O
mL	O
.	O

Patients	O
with	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
≥	O
200	O
pg/	O
mL	O
(	O
High	O
-	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
,	O
n=170	O
)	O
had	O
more	O
advanced	O
heart	B:C0018801
failure	I:C0018801
characteristics	O
,	O
including	O
lower	O
EF	I:C0743400
(	O
25.0	O
±8.6	O
%	O
vs.	O
28.1±8.0	O
%	O
,	O
P=0.0008	O
)	O
,	O
than	O
those	O
with	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
<	O
200	O
pg/	O
mL	O
.	O

Patients	O
with	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
≥	O
200	O
pg/	O
mL	O
(	O
High	O
-	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
,	O
n=170	O
)	O
had	O
more	O
advanced	O
heart	O
failure	I:C0018801
characteristics	O
,	O
including	O
lower	B:C0743400
EF	I:C0743400
(	O
25.0	O
±8.6	O
%	O
vs.	O
28.1±8.0	O
%	O
,	O
P=0.0008	O
)	O
,	O
than	O
those	O
with	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
<	O
200	O
pg/	O
mL	O
.	O

Patients	O
with	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
≥	O
200	O
pg/	O
mL	O
(	O
High	O
-	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
,	O
n=170	O
)	O
had	O
more	O
advanced	O
heart	O
failure	I:C0018801
characteristics	O
,	O
including	O
lower	O
EF	I:C0743400
(	O
25.0	O
±8.6	O
%	O
vs.	O
28.1±8.0	O
%	O
,	O
P=0.0008	O
)	O
,	O
than	O
those	O
with	O
B	B:C0054015
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
<	O
200	O
pg/	O
mL	O
.	O

In	O
the	O
High	O
-	O
B	B:C0054015
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
patients	O
,	O
peak	O
oxygen	I:C0429693
uptake	I:C0429693
(	O
V̇O2	O
)	O
was	O
significantly	O
increased	O
by	O
8.3±16.2	O
%	O
during	O
the	O
ET	O
program	O
,	O
and	O
changes	O
in	O
peak	O
V̇O2	I:C0429693
inversely	O
correlated	O
with	O
changes	O
in	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
(	O
R=-	O
0.453	O
,	O
P<	O
0.0001	O
)	O
and	O
changes	O
in	O
ventilatory	O
efficiency	O
(	O
V̇E	O
/	O
V̇CO2	O
slope	O
)	O
(	O
R=-0.439	O
,	O
P<	O
0.0001	O
)	O
.	O

In	O
the	O
High	O
-	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
patients	O
,	O
peak	B:C0429693
oxygen	I:C0429693
uptake	I:C0429693
(	O
V̇O2	O
)	O
was	O
significantly	O
increased	O
by	O
8.3±16.2	O
%	O
during	O
the	O
ET	O
program	O
,	O
and	O
changes	O
in	O
peak	O
V̇O2	I:C0429693
inversely	O
correlated	O
with	O
changes	O
in	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
(	O
R=-	O
0.453	O
,	O
P<	O
0.0001	O
)	O
and	O
changes	O
in	O
ventilatory	O
efficiency	O
(	O
V̇E	O
/	O
V̇CO2	O
slope	O
)	O
(	O
R=-0.439	O
,	O
P<	O
0.0001	O
)	O
.	O

In	O
the	O
High	O
-	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
patients	O
,	O
peak	O
oxygen	I:C0429693
uptake	I:C0429693
(	O
V̇O2	B:C0429693
)	O
was	O
significantly	O
increased	O
by	O
8.3±16.2	O
%	O
during	O
the	O
ET	O
program	O
,	O
and	O
changes	O
in	O
peak	O
V̇O2	I:C0429693
inversely	O
correlated	O
with	O
changes	O
in	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
(	O
R=-	O
0.453	O
,	O
P<	O
0.0001	O
)	O
and	O
changes	O
in	O
ventilatory	O
efficiency	O
(	O
V̇E	O
/	O
V̇CO2	O
slope	O
)	O
(	O
R=-0.439	O
,	O
P<	O
0.0001	O
)	O
.	O

In	O
the	O
High	O
-	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
patients	O
,	O
peak	O
oxygen	I:C0429693
uptake	I:C0429693
(	O
V̇O2	O
)	O
was	O
significantly	O
increased	O
by	O
8.3±16.2	O
%	O
during	O
the	O
ET	O
program	O
,	O
and	O
changes	O
in	O
peak	B:C0429693
V̇O2	I:C0429693
inversely	O
correlated	O
with	O
changes	O
in	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
(	O
R=-	O
0.453	O
,	O
P<	O
0.0001	O
)	O
and	O
changes	O
in	O
ventilatory	O
efficiency	O
(	O
V̇E	O
/	O
V̇CO2	O
slope	O
)	O
(	O
R=-0.439	O
,	O
P<	O
0.0001	O
)	O
.	O

In	O
the	O
High	O
-	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
patients	O
,	O
peak	O
oxygen	I:C0429693
uptake	I:C0429693
(	O
V̇O2	O
)	O
was	O
significantly	O
increased	O
by	O
8.3±16.2	O
%	O
during	O
the	O
ET	O
program	O
,	O
and	O
changes	O
in	O
peak	O
V̇O2	I:C0429693
inversely	O
correlated	O
with	O
changes	O
in	O
B	B:C0054015
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
(	O
R=-	O
0.453	O
,	O
P<	O
0.0001	O
)	O
and	O
changes	O
in	O
ventilatory	O
efficiency	O
(	O
V̇E	O
/	O
V̇CO2	O
slope	O
)	O
(	O
R=-0.439	O
,	O
P<	O
0.0001	O
)	O
.	O

In	O
the	O
High	O
-	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
patients	O
,	O
peak	O
oxygen	I:C0429693
uptake	I:C0429693
(	O
V̇O2	O
)	O
was	O
significantly	O
increased	O
by	O
8.3±16.2	O
%	O
during	O
the	O
ET	O
program	O
,	O
and	O
changes	O
in	O
peak	O
V̇O2	I:C0429693
inversely	O
correlated	O
with	O
changes	O
in	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
(	O
R=-	O
0.453	O
,	O
P<	O
0.0001	O
)	O
and	O
changes	O
in	O
ventilatory	O
efficiency	O
(	O
V̇E	O
/	O
V̇CO2	B:C0429247
slope	O
)	O
(	O
R=-0.439	O
,	O
P<	O
0.0001	O
)	O
.	O

During	O
a	O
median	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
of	O
46	O
months	O
,	O
patients	O
in	O
the	O
upper	O
tertile	O
of	O
changes	O
in	O
peak	O
V̇O2	I:C0429693
(	O
≥13.0	O
%	O
)	O
,	O
compared	O
with	O
those	O
in	O
the	O
lower	O
tertile	O
(	O
<	O
1.0	O
%	O
)	O
,	O
had	O
lower	O
rates	O
of	O
the	O
composite	O
of	O
all	O
-	O
cause	O
death	O
or	O
heart	O
failure	I:C0018801
hospitalization	O
(	O
37.9	O
%	O
vs.	O
54.4	O
%	O
,	O
P=0.036	O
)	O
and	O
all	O
-	O
cause	O
death	O
(	O
8.6	O
%	O
vs.	O
24.6	O
%	O
,	O
P=0.056	O
)	O
.	O

During	O
a	O
median	O
follow	O
-	I:C1522577
up	I:C1522577
of	O
46	O
months	O
,	O
patients	O
in	O
the	O
upper	O
tertile	O
of	O
changes	O
in	O
peak	B:C0429693
V̇O2	I:C0429693
(	O
≥13.0	O
%	O
)	O
,	O
compared	O
with	O
those	O
in	O
the	O
lower	O
tertile	O
(	O
<	O
1.0	O
%	O
)	O
,	O
had	O
lower	O
rates	O
of	O
the	O
composite	O
of	O
all	O
-	O
cause	O
death	O
or	O
heart	O
failure	I:C0018801
hospitalization	O
(	O
37.9	O
%	O
vs.	O
54.4	O
%	O
,	O
P=0.036	O
)	O
and	O
all	O
-	O
cause	O
death	O
(	O
8.6	O
%	O
vs.	O
24.6	O
%	O
,	O
P=0.056	O
)	O
.	O

During	O
a	O
median	O
follow	O
-	I:C1522577
up	I:C1522577
of	O
46	O
months	O
,	O
patients	O
in	O
the	O
upper	O
tertile	O
of	O
changes	O
in	O
peak	O
V̇O2	I:C0429693
(	O
≥13.0	O
%	O
)	O
,	O
compared	O
with	O
those	O
in	O
the	O
lower	O
tertile	O
(	O
<	O
1.0	O
%	O
)	O
,	O
had	O
lower	O
rates	O
of	O
the	O
composite	O
of	O
all	O
-	O
cause	O
death	B:C0011065
or	O
heart	O
failure	I:C0018801
hospitalization	O
(	O
37.9	O
%	O
vs.	O
54.4	O
%	O
,	O
P=0.036	O
)	O
and	O
all	O
-	O
cause	O
death	O
(	O
8.6	O
%	O
vs.	O
24.6	O
%	O
,	O
P=0.056	O
)	O
.	O

During	O
a	O
median	O
follow	O
-	I:C1522577
up	I:C1522577
of	O
46	O
months	O
,	O
patients	O
in	O
the	O
upper	O
tertile	O
of	O
changes	O
in	O
peak	O
V̇O2	I:C0429693
(	O
≥13.0	O
%	O
)	O
,	O
compared	O
with	O
those	O
in	O
the	O
lower	O
tertile	O
(	O
<	O
1.0	O
%	O
)	O
,	O
had	O
lower	O
rates	O
of	O
the	O
composite	O
of	O
all	O
-	O
cause	O
death	O
or	O
heart	B:C0018801
failure	I:C0018801
hospitalization	O
(	O
37.9	O
%	O
vs.	O
54.4	O
%	O
,	O
P=0.036	O
)	O
and	O
all	O
-	O
cause	O
death	O
(	O
8.6	O
%	O
vs.	O
24.6	O
%	O
,	O
P=0.056	O
)	O
.	O

During	O
a	O
median	O
follow	O
-	I:C1522577
up	I:C1522577
of	O
46	O
months	O
,	O
patients	O
in	O
the	O
upper	O
tertile	O
of	O
changes	O
in	O
peak	O
V̇O2	I:C0429693
(	O
≥13.0	O
%	O
)	O
,	O
compared	O
with	O
those	O
in	O
the	O
lower	O
tertile	O
(	O
<	O
1.0	O
%	O
)	O
,	O
had	O
lower	O
rates	O
of	O
the	O
composite	O
of	O
all	O
-	O
cause	O
death	O
or	O
heart	O
failure	I:C0018801
hospitalization	B:C0019993
(	O
37.9	O
%	O
vs.	O
54.4	O
%	O
,	O
P=0.036	O
)	O
and	O
all	O
-	O
cause	O
death	O
(	O
8.6	O
%	O
vs.	O
24.6	O
%	O
,	O
P=0.056	O
)	O
.	O

During	O
a	O
median	O
follow	O
-	I:C1522577
up	I:C1522577
of	O
46	O
months	O
,	O
patients	O
in	O
the	O
upper	O
tertile	O
of	O
changes	O
in	O
peak	O
V̇O2	I:C0429693
(	O
≥13.0	O
%	O
)	O
,	O
compared	O
with	O
those	O
in	O
the	O
lower	O
tertile	O
(	O
<	O
1.0	O
%	O
)	O
,	O
had	O
lower	O
rates	O
of	O
the	O
composite	O
of	O
all	O
-	O
cause	O
death	O
or	O
heart	O
failure	I:C0018801
hospitalization	O
(	O
37.9	O
%	O
vs.	O
54.4	O
%	O
,	O
P=0.036	O
)	O
and	O
all	O
-	O
cause	O
death	B:C0011065
(	O
8.6	O
%	O
vs.	O
24.6	O
%	O
,	O
P=0.056	O
)	O
.	O

In	O
the	O
multivariate	O
analysis	O
,	O
change	O
in	O
peak	B:C0429693
V̇O2	I:C0429693
was	O
a	O
significant	O
independent	O
predictor	O
of	O
the	O
composite	O
outcome	O
and	O
all	O
-	O
cause	O
death	O
.	O

In	O
the	O
multivariate	O
analysis	O
,	O
change	O
in	O
peak	O
V̇O2	I:C0429693
was	O
a	O
significant	O
independent	O
predictor	O
of	O
the	O
composite	O
outcome	O
and	O
all	O
-	O
cause	O
death	B:C0011065
.	O

Even	O
among	O
advanced	O
heart	B:C0018801
failure	I:C0018801
p	O
atient	O
s	O
with	O
high	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
,	O
an	O
ET	O
program	O
significantly	O
improved	O
exercise	O
capacity	O
,	O
and	O
a	O
greater	O
improvement	O
in	O
exercise	O
capacity	O
was	O
associated	O
with	O
greater	O
decreases	O
in	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
and	O
V̇E	O
/	O
V̇CO2	O
slope	O
and	O
more	O
favorable	O
long	I:C1333602
-	I:C1333602
term	I:C1333602
clinical	I:C1333602
outcomes	I:C1333602
.	O

Even	O
among	O
advanced	O
heart	O
failure	I:C0018801
p	O
atient	O
s	O
with	O
high	O
B	B:C0054015
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
,	O
an	O
ET	O
program	O
significantly	O
improved	O
exercise	O
capacity	O
,	O
and	O
a	O
greater	O
improvement	O
in	O
exercise	O
capacity	O
was	O
associated	O
with	O
greater	O
decreases	O
in	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
and	O
V̇E	O
/	O
V̇CO2	O
slope	O
and	O
more	O
favorable	O
long	I:C1333602
-	I:C1333602
term	I:C1333602
clinical	I:C1333602
outcomes	I:C1333602
.	O

Even	O
among	O
advanced	O
heart	O
failure	I:C0018801
p	O
atient	O
s	O
with	O
high	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
,	O
an	O
ET	O
program	O
significantly	O
improved	B:C0184511
exercise	O
capacity	O
,	O
and	O
a	O
greater	O
improvement	O
in	O
exercise	O
capacity	O
was	O
associated	O
with	O
greater	O
decreases	O
in	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
and	O
V̇E	O
/	O
V̇CO2	O
slope	O
and	O
more	O
favorable	O
long	I:C1333602
-	I:C1333602
term	I:C1333602
clinical	I:C1333602
outcomes	I:C1333602
.	O

Even	O
among	O
advanced	O
heart	O
failure	I:C0018801
p	O
atient	O
s	O
with	O
high	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
,	O
an	O
ET	O
program	O
significantly	O
improved	O
exercise	O
capacity	O
,	O
and	O
a	O
greater	O
improvement	O
in	O
exercise	O
capacity	O
was	O
associated	O
with	O
greater	O
decreases	B:C0442797
in	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
and	O
V̇E	O
/	O
V̇CO2	O
slope	O
and	O
more	O
favorable	O
long	I:C1333602
-	I:C1333602
term	I:C1333602
clinical	I:C1333602
outcomes	I:C1333602
.	O

Even	O
among	O
advanced	O
heart	O
failure	I:C0018801
p	O
atient	O
s	O
with	O
high	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
,	O
an	O
ET	O
program	O
significantly	O
improved	O
exercise	O
capacity	O
,	O
and	O
a	O
greater	O
improvement	O
in	O
exercise	O
capacity	O
was	O
associated	O
with	O
greater	O
decreases	O
in	O
B	B:C0054015
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
and	O
V̇E	O
/	O
V̇CO2	O
slope	O
and	O
more	O
favorable	O
long	I:C1333602
-	I:C1333602
term	I:C1333602
clinical	I:C1333602
outcomes	I:C1333602
.	O

Even	O
among	O
advanced	O
heart	O
failure	I:C0018801
p	O
atient	O
s	O
with	O
high	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
,	O
an	O
ET	O
program	O
significantly	O
improved	O
exercise	O
capacity	O
,	O
and	O
a	O
greater	O
improvement	O
in	O
exercise	O
capacity	O
was	O
associated	O
with	O
greater	O
decreases	O
in	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
and	O
V̇E	O
/	O
V̇CO2	B:C0429247
slope	O
and	O
more	O
favorable	O
long	I:C1333602
-	I:C1333602
term	I:C1333602
clinical	I:C1333602
outcomes	I:C1333602
.	O

Even	O
among	O
advanced	O
heart	O
failure	I:C0018801
p	O
atient	O
s	O
with	O
high	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
,	O
an	O
ET	O
program	O
significantly	O
improved	O
exercise	O
capacity	O
,	O
and	O
a	O
greater	O
improvement	O
in	O
exercise	O
capacity	O
was	O
associated	O
with	O
greater	O
decreases	O
in	O
B	O
-	I:C0054015
type	I:C0054015
natriuretic	I:C0054015
peptide	I:C0054015
level	O
and	O
V̇E	O
/	O
V̇CO2	O
slope	O
and	O
more	O
favorable	B:C1333602
long	I:C1333602
-	I:C1333602
term	I:C1333602
clinical	I:C1333602
outcomes	I:C1333602
.	O

